Law Firm Investigates ADMA Biologics for Potential Fiduciary Duty Breach
Berger Montague PC has launched an investigation into the board of directors at ADMA Biologics, Inc. (NASDAQ: ADMA), examining whether they engaged in channel-stuffing to artificially boost revenue despite declining demand for its flagship product, ASCENIV. ADMA is a biopharmaceutical company specializing in immune deficiency and infectious disease treatments. The firm's investigation centers on potential misconduct by the board that could have misled investors or improperly influenced financial performance. Shareholders are being invited to contact Berger Montague with any relevant information regarding this matter.
Tickers: $ADMA